Feasibility study of Anthracycline Based Regimen followed by Nab-Paclitaxel as adjuvant chemotherapy for elderly patients with breast cancer

Feasibility study of Anthracycline Based Regimen followed by Nab-Paclitaxel as adjuvant chemotherapy for elderly patients with breast cancer - FANAC study

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000009267

Enrollment

Registered

2012-11-10

Start date

2012-11-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer

Interventions

Anthracycline based regimen followed by 4 cycle nab-paclitaxel Nab-paclitaxel:175mg/m2 intravenously administered on day 1 every 3 weeks

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1.Histoligically comfirmed Breast cancer 2.Age>=60 and Age<=80 3.Expeceted to radical cure by operation 4.Recieving adjuvant therapy with any anthracycline regimen 5.PS0 or 1 6.Patients who can receive nab-paclitaxel treatment within 8 weeks after anthracycline regimen 7.no adjuvant therapy except athracycline regimen 8.Patients who can correctly fill out a questionnaire 9.Required baseline laboratory parameters(within 14 days before registration): Hb more than 9.0g/dl WBC>=3000/mm3 Neu>=1500/mm3 Plt>=75000/mm3 AST,ALT<=ULNx2.5 T-Bil<1.5mg/dl Crea<1.5mg/dl 10.adequate organ function 11.Written IC

Exclusion criteria

Exclusion criteria: 1.History of severe allergy to nab-paclitaxel 2.Metachronous bilateral breast cancer 3.Active another cancer 4.History hypersensitivity reaction 5.Physician judged improper to entry this trial

Design outcomes

Primary

Measure	Time frame
feasibility	—

Secondary

Measure	Time frame
safety, disease free survival	—

Countries

Japan

Contacts

Public ContactYoshimitsu Minari

Shimane University Hospital Breast and endcrine surgery

minari@med.shimane-u.ac.jp+81-853-20-2232

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026